Patents Assigned to EndoVx, Inc.
  • Patent number: 7991474
    Abstract: Method and apparatus for disrupting a gastric vagal nerve in the gastroesophageal region and testing the function and disruption of the vagal nerve. In one example embodiment, a treatment device applies ultrasound at a high energy level, such as high intensity focused ultrasound, to a vagal nerve to disrupt it and then ultrasound at a lower energy level to another portion of the vagal nerve, preferably further from the stomach, so as to stimulate the vagal nerve. Alternative ways to test the function or disruption of the vagal nerve involve using PCP-GABA, a pancreatic polypeptide, pressure changes inside the stomach, the gastric mucusol pH, a dye agent in the stomach, and other tests.
    Type: Grant
    Filed: March 25, 2008
    Date of Patent: August 2, 2011
    Assignee: Endovx, Inc.
    Inventors: William N. Aldrich, David Miller
  • Patent number: 7962225
    Abstract: Method and apparatus for disrupting a gastric vagal nerve in the gastroesophageal region and testing the function and disruption of the vagal nerve. In one example embodiment, a treatment device applies ultrasound at a high energy level, such as high intensity focused ultrasound, to a vagal nerve to disrupt it and then ultrasound at a lower energy level to another portion of the vagal nerve, preferably further from the stomach, so as to stimulate the vagal nerve. Alternative ways to test the function or disruption of the vagal nerve involve using PCP-GABA, a pancreatic polypeptide, pressure changes inside the stomach, the gastric mucusol pH, a dye agent in the stomach, and other tests.
    Type: Grant
    Filed: August 20, 2008
    Date of Patent: June 14, 2011
    Assignee: Endovx, Inc.
    Inventors: William N. Aldrich, David Miller
  • Patent number: 7783358
    Abstract: Method and apparatus for treating obesity by an energy delivery device, such as a high focus ultrasound transducer, mounted for movement along two or three axes relative to the esophagus to deliver transesophageal energy to interrupt the function of vagal nerves. Preferably, movement along a longitudinal axis of the esophagus changes the site to which the energy is directed and movement transversely along a radius of the esophagus focuses the energy on a vagal nerve. The third degree of freedom relative to the esophagus is to rotate the transducer about the longitudinal axis of the esophagus.
    Type: Grant
    Filed: February 24, 2005
    Date of Patent: August 24, 2010
    Assignee: Endovx, Inc.
    Inventors: William N. Aldrich, David Miller
  • Patent number: 7684865
    Abstract: Method and apparatus for treating obesity by use of transesophageal delivery of energy to interrupt the function of vagal nerves. The energy, which may be highly focused ultrasound energy or other types of energy is delivered through the wall of the esophagus by a device placed in the esophagus. The energy delivered is sufficient to ablate a vagal nerve on the outer wall of the esophagus.
    Type: Grant
    Filed: March 14, 2003
    Date of Patent: March 23, 2010
    Assignee: Endovx, Inc.
    Inventors: William Aldrich, David Miller
  • Patent number: 7430449
    Abstract: Method and apparatus for disrupting a gastric vagal nerve in the gastroesophageal region and testing the function and disruption of the vagal nerve. In one example embodiment, a treatment device applies ultrasound at a high energy level, such as high intensity focused ultrasound, to a vagal nerve to disrupt it and then ultrasound at a lower energy level to another portion of the vagal nerve, preferably further from the stomach, so as to stimulate the vagal nerve. Alternative ways to test the function or disruption of the vagal nerve involve using PCP-GABA, a pancreatic polypeptide, pressure changes inside the stomach, the gastric mucusol pH, a dye agent in the stomach, and other tests.
    Type: Grant
    Filed: February 24, 2005
    Date of Patent: September 30, 2008
    Assignee: EndoVx, Inc.
    Inventors: William N. Aldrich, David Miller